Asymchem Laboratories Tian Jin Co Ltd (002821) - Total Assets
Based on the latest financial reports, Asymchem Laboratories Tian Jin Co Ltd (002821) holds total assets worth CN¥20.70 Billion CNY (≈ $3.03 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Asymchem Laboratories Tian Jin Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Asymchem Laboratories Tian Jin Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Asymchem Laboratories Tian Jin Co Ltd to see how much of total assets are deployed in long-term investments.
Asymchem Laboratories Tian Jin Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Asymchem Laboratories Tian Jin Co Ltd's total assets of CN¥20.70 Billion consist of 56.7% current assets and 43.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 31.2% |
| Accounts Receivable | CN¥1.95 Billion | 9.6% |
| Inventory | CN¥1.47 Billion | 7.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥421.80 Million | 2.1% |
| Goodwill | CN¥146.18 Million | 0.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Asymchem Laboratories Tian Jin Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Asymchem Laboratories Tian Jin Co Ltd's current assets represent 56.7% of total assets in 2025, an increase from 52.7% in 2011.
- Cash Position: Cash and equivalents constituted 31.2% of total assets in 2025, up from 21.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.
Asymchem Laboratories Tian Jin Co Ltd Competitors by Total Assets
Key competitors of Asymchem Laboratories Tian Jin Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Asymchem Laboratories Tian Jin Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.69 | 7.16 | 3.68 |
| Quick Ratio | 4.91 | 6.39 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥9.67 Billion | CN¥9.59 Billion | CN¥2.95 Billion |
Asymchem Laboratories Tian Jin Co Ltd - Advanced Valuation Insights
This section examines the relationship between Asymchem Laboratories Tian Jin Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.24 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | CN¥20.28 Billion |
| Market Capitalization | $5.58 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Asymchem Laboratories Tian Jin Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Asymchem Laboratories Tian Jin Co Ltd's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Asymchem Laboratories Tian Jin Co Ltd (2011–2025)
The table below shows the annual total assets of Asymchem Laboratories Tian Jin Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥20.28 Billion ≈ $2.97 Billion |
+5.13% |
| 2024-12-31 | CN¥19.29 Billion ≈ $2.82 Billion |
-2.42% |
| 2023-12-31 | CN¥19.77 Billion ≈ $2.89 Billion |
+8.38% |
| 2022-12-31 | CN¥18.24 Billion ≈ $2.67 Billion |
+20.34% |
| 2021-12-31 | CN¥15.16 Billion ≈ $2.22 Billion |
+111.04% |
| 2020-12-31 | CN¥7.18 Billion ≈ $1.05 Billion |
+91.06% |
| 2019-12-31 | CN¥3.76 Billion ≈ $550.02 Million |
+18.00% |
| 2018-12-31 | CN¥3.19 Billion ≈ $466.12 Million |
+20.78% |
| 2017-12-31 | CN¥2.64 Billion ≈ $385.91 Million |
+7.87% |
| 2016-12-31 | CN¥2.44 Billion ≈ $357.77 Million |
+92.28% |
| 2015-12-31 | CN¥1.27 Billion ≈ $186.06 Million |
+20.16% |
| 2014-12-31 | CN¥1.06 Billion ≈ $154.84 Million |
+15.88% |
| 2013-12-31 | CN¥913.19 Million ≈ $133.63 Million |
+10.29% |
| 2012-12-31 | CN¥828.00 Million ≈ $121.16 Million |
+3.45% |
| 2011-12-31 | CN¥800.41 Million ≈ $117.13 Million |
-- |
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more